On-co-Inventions增加了肿瘤学家Michael Lock博士加入其咨询委员会,以推进癌症药物研究。 Onco-Innovations adds oncologist Dr. Michael Lock to its advisory board to advance cancer drug research.

On-co-Investmentations Limited已任命西方大学教授兼辐射肿瘤学家Michael Lock博士到其科学和临床咨询委员会任职,利用他在临床试验设计、翻译肿瘤学和癌症护理领导方面的专长。 Onco-Innovations Limited has appointed Dr. Michael Lock, a Western University professor and radiation oncologist, to its Scientific and Clinical Advisory Board, leveraging his expertise in clinical trial design, translational oncology, and cancer care leadership. Dr. 博士 Dr. Lock在安大略省癌症方案中发挥了关键作用,并为与卫生组织、原子能机构和联合国一起开展的省级和全球性倡议作出了贡献。 Lock has held key roles in Ontario’s cancer programs and contributed to provincial and global initiatives with the WHO, IAEA, and UN. 他的任命旨在支持该公司的PNKP抑制剂计划和更广泛的肿瘤学研究。 His appointment aims to support the company’s PNKP inhibitor program and broader oncology research. 该公司还根据其股权计划,向经理和顾问发放了155万个限制股份股。 The company also granted 1.155 million restricted share units to executives and consultants under its equity plan. 前瞻性声明告诫,未来的结果可能因风险和不确定因素而不同。 Forward-looking statements caution that future results may vary due to risks and uncertainties.